Redcare Pharmacy (Shop Apoth) stock hits one-year lows amid growth slowdown and profitability pressures

Redcare Pharmacy (Shop Apoth), ISIN: NL0012044747, has plunged over 38% year-to-date on Euronext Amsterdam in EUR, with shares recently touching a one-year low around 32 EUR. The online pharmacy leader faces decelerating revenue growth in core markets and margin compression despite international expansion efforts. US investors may find parallels to domestic telehealth trends but must weigh European regulatory and competitive risks.

Redcare Pharmacy (Shop Apoth) stock has faced intense selling pressure in early 2026, dropping over 38% year-to-date on Euronext Amsterdam in EUR as growth in its core German market slows and losses persist despite revenue gains. The Dutch-based online pharmacy operator, formerly Shop Apotheke, released full-year 2025 results showing revenue up just 8% to around €1.1 billion, a sharp deceleration from prior double-digit rates, with adjusted EBITDA margins slipping to 7.7%. This triggered a multi-week decline, pushing shares to a one-year low near €32 on Frankfurt in EUR, reflecting investor doubts about near-term profitability in a competitive European e-pharmacy landscape.

As of: 26.03.2026

Dr. Elena Voss, European Healthcare Equity Analyst: In a maturing online pharmacy sector, Redcare Pharmacy's pivot to efficiency amid growth headwinds offers a compelling case for patient US investors tracking digital health parallels.

Recent Earnings Expose Growth Deceleration in Core Markets

Redcare Pharmacy's 2025 annual results, released in March 2026, highlighted a marked slowdown in its dominant DACH region, where Germany accounts for over 90% of sales. Revenue in this segment reached approximately €2.4 billion for the year, but overall company growth dipped to single digits at 8%, down from 20%+ in previous years. Active customers grew a modest 4% to 1.5 million, while average orders per customer edged lower, signaling retention pressures amid intensifying competition from traditional chains and digital rivals.

Adjusted EBITDA of €85 million reflected margin compression to 7.7% from 9.2% in 2024, driven by elevated customer acquisition costs and logistics investments. Management pointed to supply chain disruptions, including labor shortages adding 10-15% to fulfillment expenses, as key factors. The stock reacted sharply, falling about 5% on Frankfurt in EUR post-earnings, with trading volumes spiking to indicate institutional selling.

Despite these challenges, the company maintained 2026 guidance for mid-single-digit revenue growth and gradual margin recovery, focusing on automation and international scaling. However, analysts view the outlook conservatively, projecting 7-10% CAGR through 2028 with EBITDA margins stabilizing near 9%. This tempered guidance underscores the market's shift from hypergrowth expectations to operational turnaround narratives.

Stock Performance Signals Deepening Investor Skepticism

The Redcare Pharmacy (Shop Apoth) stock was last seen trading around 32 EUR on Euronext Amsterdam, down over 33% in the past month and 70% year-over-year in EUR terms. Weekly declines averaged 4.61%, with volumes peaking above 660,000 shares during downturns, suggesting profit-taking and risk reduction by holders. This volatility contrasts with prior surges, like 198% in 2023, and positions the stock at a valuation of roughly 1.5x sales on Frankfurt in EUR.

Year-to-date losses of 38.34% on Euronext Amsterdam in EUR outpace broader market indices, with the stock hitting a one-year low of €32.24 recently. Earnings per share remain negative at -1.87 EUR, reinforcing concerns over sustained unprofitability. Inclusion in MDAX highlights its mid-cap relevance in German segments, though primary liquidity centers on Amsterdam.

Trading patterns show heightened activity on down days, indicative of capitulation selling rather than broad-based panic. For context, the stock's nominal value stands at 0.02 EUR per share, with 20.11 million shares outstanding, providing a straightforward ordinary share structure under ISIN NL0012044747.

Operational Backbone: Revenue Diversification Efforts

Redcare Pharmacy operates as Europe's leading online retailer of OTC drugs, beauty, and personal care products across seven markets, with DACH driving the majority. International revenue expanded from €213 million in 2021 to €540 million in 2025, representing a diversification win amid core market saturation. Netherlands sales hit €2.12 billion in 2025 projections, underscoring cross-border strength.

The company invested €50 million in warehouse expansions and AI inventory tools to counter logistics strains, yet returns lag as peers like Udea and Phoenix blend online-physical models effectively. Geographic split shows Netherlands dominance at over €2 billion annually, with overseas growth from €40 million to €823 million over five years.

This expansion mitigates German stagnation risks, where market penetration nears limits. Active customer base and order frequency metrics reveal subtle weaknesses, but volume in high-margin categories like beauty supports resilience. Management's focus on supply chain automation aims to claw back margins lost to inflation and labor issues.

Competitive Landscape and Cost Pressures Mount

In Germany, Redcare Pharmacy confronts hybrid competitors eroding pure-play online share, as chains digitize fulfillment while leveraging physical trust. Rising marketing spends for customer acquisition outpace organic gains, with CAC inflation hitting double digits. Logistics costs, up 10-15% from shortages, squeeze an already thin 7.7% EBITDA margin.

Sector-wide, e-pharmacy adoption plateaus post-pandemic, shifting battles to efficiency and loyalty. Redcare's €85 million adjusted EBITDA trails loftier pre-2025 expectations, prompting valuation rerating to 1.5x sales. Peers demonstrate hybrid viability, pressuring pure digital models on delivery speed and product range.

Regulatory scrutiny on online drug sales adds uncertainty, particularly around data privacy and prescription handling. Redcare's scale—over 1.5 million actives—provides defensibility, but execution on cost controls remains pivotal for recapturing investor confidence.

Why US Investors Should Monitor Redcare Pharmacy Now

US investors stand to gain exposure to Europe's e-pharmacy evolution, mirroring domestic telehealth booms at firms like Hims & Hers or Ro, but at depressed valuations around 1.5x sales. Redcare's international push parallels US digital health scaling, with AI logistics investments echoing efficiency plays in American healthcare tech. Consensus targets suggest 25% upside from current Frankfurt levels in EUR, appealing for value-oriented portfolios.

Amid US regulatory easing on telepharmacy, Redcare offers a hedge against domestic concentration risks, with DACH stability akin to mature US markets. ADR absence necessitates OTC or direct access via brokers, but liquidity on Euronext Amsterdam supports institutional flows. For those betting on healthcare digitization, the stock's trough pricing invites turnaround conviction.

Broader e-health tailwinds, including aging demographics and reimbursement shifts, align European trends with US opportunities. Tracking Q1 2026 results in May will clarify if margin recovery materializes, potentially catalyzing a rebound for cross-Atlantic portfolios.

Risks and Open Questions Loom Large

Persistent losses and negative EPS at -1.87 EUR raise dilution fears if capital raises prove necessary, especially with 20.11 million shares outstanding. Regulatory hurdles in prescription online sales could cap upside, while recessionary pressures hit discretionary beauty spends. Competition from hybrids threatens market share without faster innovation.

International scaling hinges on unproven traction beyond DACH, with overseas revenue at €823 million vulnerable to currency swings. Analyst consensus tempers optimism, with mid-single-digit growth unlikely to excite growth chasers. Macro factors like EUR weakness versus USD add FX volatility for US holders.

Key watchpoints include Q1 execution on automation ROI and customer metrics stabilization. Absent margin expansion, further downside to sub-30 EUR on Euronext Amsterdam remains plausible. Patient investors must balance recovery potential against execution pitfalls.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.